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Background
Vaccine elicited HIV-1 specific cross-reactive neutraliz-
ing humoral immunity may provide protection against
acquisition of HIV-1. Several studies have focussed on a
better understanding of cross-reactive neutralizing activ-
ity (CrNA) in natural infection, but only in homosexual
and heterosexual HIV-1 transmission cases.
Methods
To analyze the prevalence and characteristics of CrNA in
HIV-1 infected individuals who reported injecting drug
use as the only risk factor, we screened serum samples
from 50 male and 35 female participants of the Amster-
dam Cohort Studies (ACS) on injecting drug users (IDU)
for CrNA across a heterologous 6-viral panel. For compar-
ison, similar data from the ACS on men who have sex
with men (MSM) were available.
Results
HIV-1 infected IDU showed significantly lower geometric
mean IC50 values and a lower proportion of individuals
that was capable of neutralizing the majority of viruses in
the panel as compared to MSM. This difference was
however no longer observed when women were excluded
from the IDU group. Interestingly, three out of 50 in the
male IDU population qualified as elite neutralizer as
compared to 1 out of 299 among MSM. Multivariate ana-
lysis with viral load at setpoint, CD4+ count at setpoint,
gender and transmission route as co-variates revealed
only CD4+ count at setpoint as independently associated
with CrNA in serum.
Conclusion
CrNA prevalence and potency in HIV-1 infected IDU
was lower than in MSM. This could be attributed to the
presence of women in the cohort, rather than the route
of exposure, which could be explained by the fact that
women had a higher CD4+ T cell count at setpoint,
which was the only independent predictor for the pre-
sence of CrNA. Our data may implicate that the ability
of an HIV-1 vaccine to elicit CrNA may be lower in
women and testing for gender dependent future vaccine
efficacy may be recommended.
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